Antimicrobial Surface for Hospitals

Sharklet Technologies, Inc. is a medical-device company that has commercialized a revolutionary new surface technology, Sharklet™, a raised-surface skin that reduces the growth and spread of harmful bacteria.

Technology

Sharklet™ is a patented surface technology comprised of millions of raised microscopic nodules in diamond-shape patterns. The skin forms a continuous pattern that reduces dangerous bacteria growth on any surface. The surface cuts down on bacterial attachment, survival, and migration, and is non-toxic and biocide-free, preventing the spread of Staphylococcus, MRSA, Pseudomonas aeruginosa, and E. coli.

Market Potential

The company’s signature product, Sharklet™, can be applied to nearly any surface and medical device in healthcare settings. More than 200 people each day die from healthcare-acquired infections (HAIs). These infections cost hospitals more than $30 billion annually in the United States alone. Researchers estimate that approximately 70 percent of HAIs are preventable. In addition to saving lives, Sharklet™ could reduce healthcare costs in the U.S. by more than $20 billion annually.

Strategy

Sharklet Technologies has established secure revenue streams that it uses to develop new proprietary products. The company’s initial products, surface protection skins, are already on the market. Human urological medical devices will launch this year. Sharklet Technologies has several joint development agreements with original equipment manufacturers (OEMs) and actively commercializes products in three business segments: Sharklet Surface Protection Products, Sharklet for Manufactured Goods (OEM), and Sharklet Medical Devices.

About The University of Florida

Successfully transferring new discoveries to the marketplace is an important responsibility for one of the nation’s leading public research universities. UF has earned a reputation as a leader in commercializing discoveries that cure diseases, create jobs and make the world a better place. This reputation is the result of the collaborative working relationship between faculty generating new discoveries and the Office of Technology Licensing working to find commercial partners.
Management Team

Mark Spiecker, CEO
Mark Spiecker is Sharklet Technologies’ CEO. He oversees business development and commercialization strategies. He has more than 20 years of management experience in corporate development, operations management, mergers and acquisitions, and strategic communications.

Anthony Brennan, Founder & Chairman of Scientific Advisory Board
Anthony Brennan, Ph.D., is Sharklet Technologies’ founder. He also chairs the company’s Scientific Advisory Board. Dr. Brennan discovered and developed Sharklet™, the company’s core surface technology. He is a world-renowned research scientist specializing in biomedical materials and an endowed professor in the University of Florida’s Materials Science and Engineering department.

Jason Morton, Chief Operating Officer
Jason Morton is responsible for product development and operations. Jason has 20 years of product development experience, commercializing dozens of devices.

Shravanthi Reddy, Director of Research
Shravanthi Reddy, Ph.D., is Sharklet Technologies’ Vice President of Research and the principal investigator for product development. Her work has been funded by the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program through nine SBIR grants. Dr. Reddy earned her Ph.D. in Chemical Engineering from the University of Texas at Austin.

Elisa Dannemiller, Chief Medical Officer
Elisa Dannemiller, M.D., is the company’s Chief Medical Officer. She directs Sharklet’s clinical work, translating science into approved claims.

Contact Information
Mark Spiecker
Sharklet Technologies, Inc.
(303) 921-5789
mspiecker@sharklet.com
http://www.sharklet.com

For more information about UF startups, contact
UF TechConnect® (352) 846-1840
www.otl.ufl.edu